Background The 'placebo effect'and 'nocebo effect'are phenomena whereby beneficial
(placebo) or adverse (nocebo) effects result from the expectation that an inert substance will …

Mendelian randomization studies and randomized trials have conclusively demonstrated
that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events …

Background This cross-sectional study aimed to identify actionable factors to improve LDL-
cholesterol target achievement and overcome underuse of lipid-lowering treatments in high …

Aim Statin‐associated muscle symptoms (SAMS) are a major determinant of poor treatment
adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The …

Objective To assess the benefits and harms of lipid-lowering therapies used to prevent or
manage cardiovascular disease including bile acid sequestrants (BAS), ezetimibe, fibrates …

Introduction: Although statins have a satisfactory safety profile and are well tolerated, many
statin-treated patients report muscle symptoms in clinical practice which contribute to drug …

Aims Low-dose colchicine reduces cardiovascular risk in patients with coronary artery
disease (CAD), but absolute benefits may vary between individuals. This study aimed to …

Traumatic brain injuries (TBIs) are associated with high morbidity and mortality due to both
the original insult as well as the destructive biological response that follows. Medical …

Abstract The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, also known as
“statins” are considered first‐line pharmacologic therapy for reducing low‐density lipoprotein …

Statins are hypolipidaemic in human immunodeficiency virus (HIV) positive individuals.
However, their effect on all-cause mortality and rate of discontinuation is unclear. We …